PRAME and non-small cell lung carcinoma: For example, Pujol et al. [17] used a proprietary recombinant PRAME molecule as an immunostimulant in a Phase I safety study in NSCLC patients who had undergone surgical resection; anti-PRAME antibodies, but no CD8+ responses, were detected following four immunizations.